Description: Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for use in out-patient and hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an intravenous ultra-short-acting anesthetic, which is in final stage of clinical development for use in procedural sedation, as well as in other indications, such as general anesthesia and intensive care unit sedation. It has partnerships and license agreements with Cosmo Pharmaceuticals, Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm, Pharmascience (Pendopharm), and Mundipharma. Paion AG was founded in 2000 and is headquartered in Aachen, Germany.
Home Page: www.paion.com
Heussstrasse 25
Aachen,
52078
Germany
Phone:
49 2414 4530
Officers
| Name | Title |
|---|---|
| Dr. James Neil Phillips ChB, M.B.A., M.D., MB, MBA | CEO & Chairman of Management Board |
| Mr. Sebastian Werner | Member of Management Board & CFO |
| Ralf Penner | VP of Investor Relations & PR |
| Dr. Shaw Sorooshian | Sr. VP of Medical Affairs |
| Dr. Thomas Stoehr | Sr. VP of Devel. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 70.4225 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.0124 |
| Price-to-Sales TTM: | 2.2244 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 62 |